Clinical trial
BUILD 3: Bosentan Use in Interstitial Lung Disease
NCT00391443 · Actelion, Industry · Completed
Key facts
| NCT number | NCT00391443 |
|---|---|
| Title | BUILD 3: Bosentan Use in Interstitial Lung Disease |
| Official title | Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study. |
| Acronym | BUILD 3 |
| Lead sponsor | Actelion, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | Bosentan, Placebo |
| Enrollment | 616 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Oct 24, 2006 |
| Last update posted | Feb 4, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: